ANP Licensing Partner povides Update on Corporate Progress
Released
Released
Announcement PDF
19 November 2015
Antisense Licensing Partner Strongbridge Provides Update on Corporate Progress
Antisense Therapeutics Limited (ASX: ANP) wishes to advise that its’ Licensing Partner of
ATL1103/COR-004, Strongbridge Biopharma plc (NASDAQ: SBBP) has today provided an update on
corporate progress.
The corporate progress update also refers to advances in the clinical development of Strongbridge’s
rare endocrine disease portfolio which includes COR-004/ATL1103.
For details please refer to the Strongbridge press release which is attached.
Contact Information:
Website: www.antisense.com.au
Managing Director – Mark Diamond +61 3 9827 8999
About Antisense Therapeutics Limited
Antisense Therapeutics Limited is an Australian publicly listed biopharmaceutical drug discovery and development
company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for
large unmet markets. Antisense Therapeutics has 4 products in its development pipeline that it has in-licensed
from Isis Pharmaceuticals Inc. (ISIS), a world leader in antisense drug development and commercialisation ATL1102 (injection) which has successfully completed a Phase IIa trial in patients with relapsing-remitting
multiple sclerosis (RRMS), ATL1103 drug designed to block GHr production which in a Phase II clinical trial
reduced blood IGF-1 levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the
pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug
at the pre-clinical stage being investigated as a potential treatment for cancer.
6 WALLACE AVENUE, TOORAK VIC 3142 AUSTRALIA
TEL . +61 (3) 9827 8999 FAX +61 (3) 9827 1166 WEB WWW.ANTISENSE.COM.AU
ANTISENSE THERAPEUTICS LIMITED ABN 41 095 060 745
Press Release
Strongbridge Biopharma plc Provides Update on Corporate Progress
Strongbridge Advances Clinical Development of Rare Endocrine Disease Portfolio With
COR-003, COR-004 and COR-005
Strongbridge Expands Key Functional Area Expertise With Senior Hires
Strongbridge Provides Update on Cash Position
DUBLIN, Ireland and TREVOSE, Pa., Nov. 18, 2015 (GLOBE NEWSWIRE) -Strongbridge
Biopharma plc (NASDAQ:SBBP) today announced an update on corporate progress.
"Strongbridge has made significant progress in a short amount of time executing against its
strategic plan to become a leader in providing innovative therapeutic options to patients with
rare endocrine disorders and other rare diseases," said Matthew Pauls, president and chief
executive officer of Strongbridge Biopharma. "With the recent successful completion of several
important corporate initiatives, including two transactions for COR-004 and COR-005,
re-domiciliation to Ireland and our U.S. public offering, Strongbridge is focused on accelerating
the development of its rare endocrine disease portfolio," Pauls added.
Strongbridge Advances Clinical Development of Rare Endocrine Disease Portfolio
with COR-003, COR-004 and COR-005
Strongbridge's lead product candidate, COR-003 (levoketoconazole), is currently being studied
in a pivotal Phase 3 clinical trial for the treatment of endogenous Cushing's Syndrome. Patient
enrollment in the Phase 3 trial continues to progress. As previously stated, the Company expects
to report top-line data during the first half of 2017 and to file for regulatory approval in the
second half of 2017. For more information about the trial, visit:
http://cushingssyndromestudy.com/
(http://www.globenewswire.com/newsroom/ctr?
d=10156608&l=7&u=http%3A%2F%2Fcushingssyndromestudy.com%2F).
Results from a secondary efficacy analysis of the completed Phase 2 trial for COR004, a novel second-generation antisense compound, which is in clinical development for
acromegaly and designed to block the synthesis of growth hormone receptor (GHr) thereby
reducing levels of insulin-like growth factor-1 (IGF-1) in the blood, were recently presented at
the Society for Endocrinology BES2015 conference. These data provide further evidence for the
efficacy of COR004 and its ability to inhibit growth hormone receptor (GHR) expression.
COR-003 and COR-005, a next-generation somatostatin analog (SSA) with a unique receptor
affinity profile, being investigated for the treatment of acromegaly, with potential additional
applications in Cushing's disease and neuroendocrine tumors, have received orphan designation
from both the European Medicines Agency and the U.S. Food and Drug Administration.
The Company is pursuing orphan designation for COR-004, and engaging with regulatory
agencies to determine future development plans.
Strongbridge Expands Key Functional Area Expertise with Senior Hires
Strongbridge has expanded its clinical development, regulatory affairs, operations and finance
teams to help execute against the Company's strategic plans. Recently, the Company welcomed
Fredric Cohen, M.D., vice president, clinical research & development; James R. Englund, CPA,
CMA, vice president, corporate controller; Susan Thornton, vice president, regulatory affairs;
and Peter J. Valentinsson, vice president, global technical operations.
Fredric Cohen, M.D., is an endocrinologist with more than 20 years of therapeutics
development and related experience in the life science industry, more recently focused in
rare disease and specialty products, at companies, including Aptalis Pharma, Johnson &
Johnson and Eli Lilly & Company.
James R. Englund, CPA, CMA, has nearly 30 years of experience in finance and
accounting fields, with nearly 15 years in pharmaceutical industry finance for
commercial-stage companies, including Auxilium Pharmaceuticals, Inc., where he most
recently served as corporate controller for nearly 10 years. Jim has also held positions at
IMS Health Corporation and Aventis Behring Corporation.
Susan Thornton has nearly 20 years of senior regulatory affairs experience with specialty
pharmaceutical companies, including Antares Pharma, Aptalis Pharma, Inc., Barrier
Therapeutics and Teva Pharmaceuticals USA.
Peter J. Valentinsson has more than 25 years of technical operations experience and has
held positions of increasing seniority at both large pharmaceutical and biotechnology
companies, including NPS Pharmaceuticals, Inc., which was recently acquired by Shire,
and Schering-Plough Research Institute.
"We are excited to welcome Fred, Jim, Sue and Pete to Strongbridge," said
Matthew Pauls, president and chief executive officer of Strongbridge
Biopharma. "Collectively, their rare disease and specialty therapeutic expertise brings to
Strongbridge the caliber of experience and passion that we need to accelerate the Company's
growth and ability to achieve upon its vision of addressing unmet needs for the rare disease
community," Pauls added.
Strongbridge Provides Update on Cash Position
As of September 30, 2015, Strongbridge had pro forma cash and cash equivalents of $62.2
million, which included proceeds from the U.S. IPO offering that priced on October 16, 2015.
The Company believes it has sufficient existing cash and cash equivalents to fund planned
operations into 2017.
About Strongbridge Biopharma
Strongbridge Biopharma's strategic focus is to build a biopharmaceutical company focused on
the development, in-licensing, acquisition and eventual commercialization of complementary
product candidates across multiple franchises that target rare diseases. Strongbridge
Biopharma's lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor that is
currently being studied in the global Phase 3 trial for the treatment of endogenous Cushing's
syndrome. COR-003 and COR-005 have received orphan designation from both the European
Medicines Agency and the U.S. Food and Drug Administration, and the Company is pursuing
orphan designation for COR-004. Strongbridge Biopharma recently expanded its rare endocrine
disease franchise with the completion of transactions for two Phase 2 product candidates:
COR004, a novel second-generation antisense compound, which is in clinical development for
the treatment of acromegaly and designed to block the synthesis of growth hormone receptor
(GHr), thereby reducing levels of insulin-like growth factor-1 (IGF-1) in the blood; and
COR-005, a next-generation somatostatin analog (SSA) with a unique receptor affinity profile,
being investigated for the treatment of acromegaly, with potential additional applications in
Cushing's disease and neuroendocrine tumors. Strongbridge Biopharma's intent is to
independently commercialize its rare endocrine assets in key global markets.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and
uncertainties. All statements, other than statements of historical facts, contained in this press
release, are forward-looking statements. These statements relate to future events and involve
known and unknown risks, including, without limitation, uncertainties regarding Strongbridge's
strategy, plans, future financial position, outcomes of product development efforts and
objectives of management for future operations. The words "anticipate," "estimate," "expect,"
"intend," "may," "plan," "potential," "project," "target,"
"will," "would," or the negative of these terms or other similar expressions are intended to
identify forward-looking statements, although not all forwardlooking statements contain these
identifying words. These forward-looking statements are based on current expectations,
estimates, forecasts and projections and are not guarantees of future performance or
development and involve known and unknown risks, uncertainties and other factors. The
forward-looking statements contained in this press release are made as of the date of this press
release, and Strongbridge Biopharma does not assume any obligation to update any
forward-looking statements except as required by applicable law.
CONTACT: Corporate and Media Relations
Elixir Health Public Relations
Lindsay M. Rocco
+1 862‐596‐1304
lrocco@elixirhealthpr.com (mailto:lrocco@elixirhealthpr.com)
Investor Relations
ICR Inc.
Stephanie Carrington
+1 646‐277‐1282
Stephanie.Carrington@icrinc.com (mailto:Stephanie.Carrington@icrinc.com)
USA
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. +1 610‐254‐9200
Fax. +1 215‐355‐7389
()
Strongbridge Biopharma plc
Share your feedback
Discover